Physician profile
Dhrupad Joshi
NPI 1891103735
$3,560.55
in general payments reported to CMS, 2019-2025
29 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $283 · 2022: $525 · 2023: $527 · 2024: $1,057 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534 · Education: $98.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.12 |
| Education | $98.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $544.47 | 2021-2025 | Xcopri |
| Biogen, INC. | $432.62 | 2021-2025 | Vumerity, Leqembi, Tysabri |
| Lundbeck LLC | $301.86 | 2021-2025 | Vyepti |
| Tg Therapeutics, INC. | $260.54 | 2023-2025 | |
| Harmony Biosciences LLC | $214.04 | 2024-2025 | |
| Pfizer INC. | $193.81 | 2023-2025 | |
| Amgen INC. | $172.63 | 2025 | Uplizna |
| Ucb, INC. | $139.45 | 2024 | Zilbrysq, Nayzilam |
| Alexion Pharmaceuticals, INC. | $138.69 | 2024-2025 | Ultomiris |
| Octapharma USA, INC. | $135.96 | 2021-2023 | Panzyga |
| Novartis Pharmaceuticals Corporation | $135.77 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $135.57 | 2021-2025 | Andexxa, Wainua |
| Noctrix Health, INC. | $135.02 | 2024 | Nidra |
| Gilead Sciences, INC. | $120.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $58.77 | 2022-2023 | Rytary |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $52.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $51.37 | 2021 | |
| Eisai INC. | $49.63 | 2023-2024 | |
| Neurelis, INC. | $40.13 | 2021-2023 | Valtoco |
| Genentech USA, INC. | $38.55 | 2022-2024 | Ocrevus |
| Argenx US, INC. | $31.42 | 2024 | Vyvgart |
| Lilly USA, LLC | $31.24 | 2024 | Kisunla |
| Ani Pharmaceuticals, INC. | $27.07 | 2024 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $21.97 | 2025 | Inbrija |
| Acadia Pharmaceuticals INC | $21.16 | 2025 | Nuplazid |
| Abbvie INC. | $20.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.19 | 2022 | |
| Nevro Corp. | $18.85 | 2023 | Senza |
| Alnylam Pharmaceuticals INC. | $16.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhrupad Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.